Definium Therapeutics Announces New Employee Inducement Grants

Article content

NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 70,860 common shares of the Company (the “Options”) with effective grant dates of April 6, 2026 and April 20, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.

Article content

Article content

The Options were granted as a material inducement to each employee’s employment and were approved by Definium’s Compensation Committee on April 3, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside Definium’s equity incentive plans.

Article content

Article content

Article content

About Definium Therapeutics

Article content

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content

Investors:

Article content

Article content

Gitanjali Jain

Article content

Article content

VP, Head of Investor Relations

Article content

Article content

Article content

Media:

Article content

Article content

Article content